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Introduction: An increasing number of targeted drugs have been tested for the treatment of nasopharyngeal
carcinoma (NPC). However, targeted therapy-related oncogenic mutations have not been fully evaluated. This
study aimed to detect targeted therapy-related oncogenic mutations in NPC and to determine which targeted
therapy might be potentially effective in treating NPC.
Methods: By using the SNaPshot assay, a rapid detection method, 19 mutation hotspots in 6 targeted therapy-related
oncogenes were examined in 70 NPC patients. The associations between oncogenic mutations and clinicopathologic
factors were analyzed.
Results: Among 70 patients, 12 (17.1%) had mutations in 5 oncogenes: 7 (10.0%) had v-kit Hardy-Zuckerman 4 feline
sarcoma viral oncogene homolog (KIT) mutation, 2 (2.8%) had epidermal growth factor receptor (EGFR) mutation,
1 (1.4%) had phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutation, 1 (1.4%) had
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation, and 1 (1.4%) had simultaneous EGFR and v-Raf murine
sarcoma viral oncogene homolog B1 (BRAF) mutations. No significant differences were observed between oncogenic
mutations and clinicopathologic characteristics. Additionally, these oncogenic mutations were not associated with
tumor recurrence and metastasis.
Conclusions: Oncogenic mutations are present in NPC patients. The efficacy of targeted drugs on patients with the
related oncogenic mutations requires further validation.
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Nasopharyngeal carcinoma (NPC) is characterized by a
unique geographic distribution [1]. The incidence of
NPC in South China is one of the highest worldwide
(20 to 30 per 100,000) [2]. Radiotherapy with or without
chemotherapy is the standard of care for non-metastatic
disease [3]. With the development of radiotherapy
techniques, the prognosis of early-stage NPC has been
obviously improved, as indicated by a 5-year local* Correspondence: zhangli6@mail.sysu.edu.cn
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unless otherwise stated.control rate of 95% and a 5-year disease-free survival
rate of 77% [4]. Distant metastasis, which occurred in
approximately 20% of patients with locally advanced
disease, was the main reason for treatment failure [4]. For
patients with metastatic disease, the median overall
survival (OS) was less than 2 years.
Currently, with the rapid development of molecular
medicine, an increasing number of targeted drugs have
been developed and used in cancer treatment, thereby
providing new options for the management of NPC.
Several clinical trials testing targeted therapy in NPC
demonstrated the promising efficacy of targeted drugs
such as cetuximab [5], bevacizumab [6], and sorafenib
[7]. However, none of these targeted drugs have been
approved by the Food and Drug Administration (FDA) for
use in NPC due to the limited improvement on survival.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinical characteristics of 70 patients with
nasopharyngeal carcinoma (NPC)























Zhang et al. Chinese Journal of Cancer  (2015) 34:10 Page 2 of 7In fact, not all of the patients could benefit from targeted
therapy. The sensitivity of targeted drugs is related to
the genetic makeup of individual tumors; therefore,
the identification of somatic mutations is increasingly
important in the clinical management of cancer [8].
Different types of targeted drugs have been tested in
clinical trials for NPC, including monoclonal antibodies
against epidermal growth factor receptor (EGFR) and
vascular endothelial growth factor (VEGF) as well as
small-molecule tyrosine kinase inhibitors (TKIs) [5-7].
These drugs had different mechanisms of inhibiting
molecular signaling pathways. Monoclonal antibodies
against EGFR, such as cetuximab and nimotuzumab, bind
to EGFR to block its downstream signaling pathway.
Additionally, the monoclonal antibody against VEGF
had anti-angiogenic effects. Among small-molecule
TKIs, such as sorafenib, famitinib, and dasatinib, most
were multi-targeted TKIs. However, until now, few
studies have focused on the roles of oncogenic mutations
in NPC, and the results are controversial. No specific
oncogenic target has yet been identified in NPC for
targeted therapy [9].
Here, we aimed to evaluate the prevalence of targeted
therapy-related oncogenic mutations in NPC using theSNaPshot assay and to identify potentially effective targets
in NPC. We mainly focused on the EGFR signaling pathway
components, including EGFR, phosphatidylinositol-4,5-
bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA),
Kirsten rat sarcoma viral oncogene homolog (KRAS), and
v-Raf murine sarcoma viral oncogene homolog B1
(BRAF). In addition, the v-kit Hardy-Zuckerman 4 feline
sarcoma viral oncogene homolog (KIT) gene was also
analyzed. All of these factors are common hotspots
for mutations in cancer.Methods
Patient selection
Consecutive patients who were pathologically diagnosed
with NPC between April 2012 and December 2012 at the
Sun Yat-sen University Cancer Center (Guangzhou, China)
for whom fresh-frozen tissue samples were available were
enrolled. The clinicopathologic information of all patients
was collected, including sex, age, tumor stage, pathologic
type, and treatment regimen. Tumor stage was classified
according to the Union for International Cancer Control
(UICC) 2010 NPC TNM staging system. Fresh nasopharyn-
geal tissue samples were obtained from all patients.
Informed consent forms outlining tissue collection and
clinical information analyses were signed by all patients.
The protocol was approved by the institutional ethics
committee of the Sun Yat-sen University Cancer Center.DNA extraction
Fresh frozen tissues confirmed to be NPC by hematoxylin
and eosin staining were obtained and stored in microtubes
at −80°C. DNA was extracted by using the QIAamp DNA
extraction kit (QIAGEN, Shanghai, China) according to
the manufacturer’s protocol. Briefly, these tissues were
transferred to 1.5-mL Eppendorf tubes, treated with
animal tissue lysis buffer, and incubated with proteinase K
at 56°C overnight. After tissue lysis, 200 μL alkaline lysis
buffer and 200 μL ethanol were added. The lysate was
then transferred to the QIAamp MinElute column, 20 μL
elution buffer was added, and the DNA was collected.SNaPshot assay
Multiple oncogenic mutations were detected with the
SNaPshot multiplex kit (QIAGEN, Shanghai, China), which
involves multiplex polymerase chain reaction (PCR), multi-
plexed single-base primer extension, and capillary electro-
phoresis. The experiment was performed according to the
instructions of the kit. Five oncogenes, EGFR, PIK3CA,
KRAS, BRAF, and KIT, were detected, which were mainly
involved in the EGFR signaling pathway. The SNaPshot
assay is more flexible and slightly more sensitive than direct
sequencing [10,11].
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The associations between oncogenic mutations and
clinicopathologic parameters were assessed with
Fisher’s exact test or Student’s t test. A P value of
less than 0.05 was considered significant. SPSS soft-




A total of 70 patients were enrolled for the analysis.
Among the 70 patients, 46 were men and 24 were
women, with a median age of 46 years (range, 24 to
73 years). According to the WHO histological classifica-
tion, all patients were diagnosed with non-keratinizingFigure 1 Representative images showing the KRAS mutation detected
no mutation peak; this sample was from a confirmed patient with no muta
(red arrow head).undifferentiated carcinoma. The median follow-up dur-
ation was 25.8 months, with January 2014 as the last
follow-up date. Only 11 patients had tumor recurrence
or metastasis. The baseline characteristics of all patients
are shown in Table 1.
Oncogenic mutation profiles
Nineteen mutation hotspots of 5 targeted therapy-related
oncogenes were examined in 70 NPC patients. Among the
70 patients, 12 (17.1%) had mutations in 5 oncogenes: 7
(10.0%) had KIT (M541L) mutation, 2 (2.8%) had EGFR
(T790M) mutation, 1 (1.4%) had PIK3CA (H1047R)
mutation, 1 (1.4%) had KRAS (G13D) mutation, and 1
(1.4%) had simultaneous EGFR and BRAF (V600E)
mutations (Figures 1 and 2).by the SNaPshot assay. A, a negative control sample with
tion. B, a positive sample with a typical KRAS mutation peak
Figure 2 Representative images showing simultaneous BRAF and EGFR mutations detected by the SNaPshot assay. A, a negative control
sample with no mutation peak; this sample was from a confirmed patient with no mutations. B, a positive sample with typical BRAF and EGFR
mutation peaks (red arrow heads).
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clinicopathologic characteristics
Between the mutation and wild-type groups, no significant
differences were observed for the clinicopathologic fac-
tors, including age, sex, clinical stage, EBV copy number,
and recurrence/metastasis (Table 2). Only 11 patients had
disease recurrence and metastasis; hence, survival analysis
was not performed in this study.
Discussion
In this study, with the rapid detection method, we found
that KIT mutation was the most frequent in NPC
followed by EGFR mutation, whereas PI3KCA, KRAS,
and BRAF mutations were less frequent, which was
consistent with the results of a previous study [12].No obvious association was found between oncogenic
mutations and clinicopathologic factors. Although another
retrospective study showed that NPC patients who had
recurrence or developed metastases had high mutation
frequencies due to the relatively short follow-up duration,
our study did not find the same result.
KIT is a transmembrane tyrosine kinase receptor
encoded by the proto-oncogene C-KIT. The activation of
KIT is associated with tumor proliferation, differentiation,
adhesion, and apoptosis [13]. KIT was reported to be
expressed in 33%-88% of NPCs [14-16]. Additionally, KIT
mutation was also reported in our previous study [17]. It
is well known that the KIT oncogene inhibitor imatinib
has been widely used in clinical practice and has been
approved for use in melanoma, gastrointestinal stromal
Table 2 Associations between oncogenic mutations and
clinical characteristics of NPC









I + II 3 13
III + IV 9 45
EBV copy number 0.092
>1,000 11 38
<1,000 1 20
Recurrence or metastasis 0.675
Yes 1 10
No 11 48
The Fisher’s exact test was performed in this analysis.
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patients with KIT mutations [18,19]. In our study, a KIT
mutation in exon 10 (M541L), which is different than the
functional mutations in exon 9 and exon 11 [20], occurred
in 10% of NPC patients. However, the KIT (M541L) muta-
tion was considered a gene polymorphism in CML. A
myeloid cell line with the KIT (M541L) mutation was sen-
sitive to imatinib in preclinical studies [21,22]. In addition,
in previous experiments, imatinib could inhibit the prolif-
eration of NPC cell lines (CEN-1, CNE2, Hone-1 C-666,
SUNE-1, and 5-8 F) in a dose-dependent manner [17].
Thus, whether imatinib could be used in NPC patients
with KIT mutations remains unknown, and further clinical
trials are necessary to validate the efficacy of imatinib for
treating NPC patients with KIT mutations.
EGFR is also a transmembrane tyrosine kinase recep-
tor. EGFR overexpression in NPC is quite common and
has been reported with a prevalence as high as 80% in
primary NPC biopsies [23-25]. It has been proven that
EGFR overexpression was indicative of poor prognosis
and was associated with a low local control rate and
short survival [26,27]. Thus, EGFR is considered an
important target in NPC. However, EGFR mutations are
reported to have an extremely low prevalence (0-1%) in
NPC [28,29]. In our study, EGFR mutations were
detected in 3 (4.3%) patients, all of whom had the
T790M mutation in exon 20. In a phase II clinical trial
of gefitinib for treating NPC, there was no response. The
median progression-free survival (PFS) and OS were 4
and 16 months, respectively [30]. This result could beexplained by the low EGFR mutation rate in NPC. In
addition, patients with the T790M mutation showed
primary resistance to gefitinib [31]. However, a new
generation of EGFR TKIs, including AZD9291 and
CO-1686, that target T790M has been recently developed
[32,33]. Perhaps a small subset of NPC patients could
benefit from these new EGFR TKIs.
Phosphatidylinositol 3 kinase (PI3K) is involved in diverse
cellular functions, including cell proliferation, differenti-
ation, motility, and survival. The PI3K-AKT pathway plays
an important role in different tumor types. Activation of
the PI3K pathway is significant in the development of NPC
[34,35]. The PI3KCA mutation rate was low. In the present
study, only 1 patient (1.4%) had PI3KCA (H1047Y) muta-
tion. The treatment of NPC cells with the PI3K inhibitor
LY294002 led to the inhibition of AKT activation [36]. In
addition, another inhibitor, MK-2206, which targets AKT,
abrogates the AKT signaling [37]. These drugs are currently
being evaluated in clinical trials. The PI3K-AKT pathway
might be a new target in NPC [29].
The RAS/RAF/ERK pathway, which also plays an
important role in tumor development, is downstream
of EGFR [38,39]. Previous studies detected no KRAS
mutations in NPC specimens or cell lines [29,40]. In
the present study, KRAS mutations were detected in
only 1 patient. Mutations of the Ras signaling path-
way might lead to cetuximab resistance in NPC [41].
Furthermore, the BRAF (V600E) mutation was detected in
only 1 patient. BRAF mutations were more common in
melanoma, and a BRAF inhibitor has been approved
for the treatment of melanoma. Although the mutation
rate is not high, BRAF is also a candidate biomarker for
targeted therapy.
This study has several limitations. First, only 5 oncogenes
related to the available targeted drugs were selected in our
study. Second, the follow-up duration was short, and
survival analysis was not conducted. Third, compared with
deep sequencing, the SNaPshot method provides
high-throughput data and is less expensive; however,
it was not adequate to detect all genes in NPC. Therefore,
our team is preparing to conduct whole-genome sequencing
for NPC, which might provide more molecular information
for NPC in the near future.
Conclusions
In our study, we found that 10% of patients with NPC
had KIT mutations that were not at the commonly
mutated sites. Additionally, other hotspot oncogenic
mutations were infrequent in NPC patients from South
China. The discovery of new therapeutic targets is
underway.
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